Gene · 4437
Papers3,191
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1 to 20 of 3,191
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| [Mechanism of Apoptosis for Corynoline-Mediated Reversing the Drug Resistance of AML HL-60/ADR Cells]. | Zhongguo Shi Yan Xue Ye Xue Za Zhi | 2026 | 42802433 | PubTator, text mining | PubMed |
| Integrated Molecular Profiling of Endometrial Cancer: NGS Findings, MSI/MMR Status, Histopathological Features, and TCGA-Inspired Molecular Classification. | Biomedicines | 2026 | 42792624 | PubTator, text mining | PubMed |
| Heterozygous germline mutations in MSH3, and probably MLH3, act as classical tumour suppressors, leading to excess somatic deletion mutations, signature ID4 and increased colorectal cancer risk. | Gut | 2026 | 42728028 | PubTator, text mining | PubMed |
| Unscheduled DNA synthesis reveals a DNA repair hotspot and biomarker of somatic instability at the expanded-CAG repeat tract in the huntingtin gene. | bioRxiv | 2026 | 42619847 | PubTator, text mining | PubMed |
| DNA Repair Pathway Variants Are Enriched in Individuals with Biallelic AAGGG CANVAS and RFC1-Related Disease. | Mov Disord | 2026 | 42473260 | PubTator, text mining | PubMed |
| Tissue-specific CTG•CAG expansion rate and disease severity are modified by DNA repair genes expression levels in myotonic dystrophy type 1 patients. | DNA Repair (Amst) | 2026 | 42419013 | PubTator, text mining | PubMed |
| A Case of Pancreatic Cancer with High Tumor Mutation Burden Showing a Remarkable Response to Pembrolizumab. | Surg Case Rep | 2026 | 42404091 | PubTator, text mining | PubMed |
| Mismatch repair dissection by in vivo RNAi reveals dose-dependent modulators of somatic instability and proteome remodeling in Huntington's disease. | bioRxiv | 2026 | 42395360 | PubTator, text mining | PubMed |
| Clinical and genomic characteristics of primary resistant disease to first-line immuno-oncology plus VEGFR inhibitor therapy in metastatic renal cell carcinoma. | Sci Rep | 2026 | 42380403 | PubTator, text mining | PubMed |
| Somatic CRISPR editing of Msh3 mitigates Huntington's disease pathology in mice. | bioRxiv | 2026 | 42327018 | PubTator, text mining | PubMed |
| Genetic or pharmacological disruption of the MSH3 Y245/K246 IDL binding pocket slows CAG repeat expansion. | NAR Mol Med | 2026 | 42317610 | PubTator, text mining | PubMed |
| Hereditary Cancer Genetic Testing for All? A Retrospective Analysis on Genetic Mutations Found in Individuals Not Meeting NCCN® Guidelines. | Eur J Breast Health | 2026 | 42317085 | PubTator, text mining | PubMed |
| Comprehensive Genomic Profiles of Patients With Biliary Tract Cancer. | Cancer Med | 2026 | 42286843 | PubTator, text mining | PubMed |
| Novel African American Colorectal Cancer MSH3 Variants Associate With Major Genomic Instability. | Hum Mutat | 2026 | 42253507 | PubTator, text mining | PubMed |
| Computational Analysis of Differentially Expressed Genes in Arsenic-Induced Carcinogenesis and Their Effect on Human Repair Mechanisms. | Environ Mol Mutagen | 2026 | 42219787 | PubTator, text mining | PubMed |
| Automotive gasoline-induced epigenetic modifications and genotoxic effects in occupationally exposed workers. | Toxicology | 2026 | 42190885 | PubTator, text mining | PubMed |
| PLSCR1 drives chemoresistance in TNBC via METTL3/IGF2BP3-mediated mRNA stabilization and EGFR-MAPK pathway activation. | Cell Death Dis | 2026 | 42140933 | PubTator, text mining | PubMed |
| Genomic characterization of DNA damage response pathway mutations reveals their adverse impact on EGFR-TKI efficacy in non-small cell lung cancer. | Respir Res | 2026 | 42092972 | PubTator, text mining | PubMed |
| A potential mutation-defined POLE/MMR/TP53 group classifications to stratify BRCA wild type epithelial ovarian cancer. | J Ovarian Res | 2026 | 42063040 | PubTator, text mining | PubMed |
| Inflammation Drives Phosphorylation and Acetylation of MutS Homolog 3 and Interaction with Cytosolic HDAC6. | J Cancer | 2026 | 42038019 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4437/papers